OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
| Revenue (TTM) | $587.90M |
| Gross Profit (TTM) | $114.48M |
| EBITDA | $-78.17M |
| Operating Margin | -15.30% |
| Return on Equity | -5.88% |
| Return on Assets | -5.52% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $1.59 |
| Price-to-Book | 1.07 |
| Price-to-Sales (TTM) | 1.94 |
| EV/Revenue | 2.324 |
| EV/EBITDA | 24.89 |
| Quarterly Earnings Growth (YoY) | -12.60% |
| Quarterly Revenue Growth (YoY) | 4.30% |
| Shares Outstanding | $746.33M |
| Float | $323.73M |
| % Insiders | 50.52% |
| % Institutions | 27.56% |
Volatility is currently expanding
OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.
Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OPK and any ticker you trade — then tracks every position and per-strategy win rate.
